Evolus receives positive CHMP opinion for Nuceiva in the European Union

Evolus

26 April 2019 - European Commission approval anticipated within 90 days.

Evolus today announced the EMA's Committee for CHMP has issued a positive opinion on the Nuceiva marketing authorisation application.

The CHMP opinion is a scientific recommendation for marketing authorisation to the European Commission, which will now review the recommendation and deliver its final decision on the Company’s marketing authorisation application. The decision will be applicable to all 28 European Union member states plus Iceland, Norway and Liechtenstein.

Read Evolus press release

Michael Wonder

Posted by:

Michael Wonder